William Gerhart

Bill Gerhart has more than 20 years’ experience building high-performance execution teams to develop new therapeutics for serious diseases. Bill is currently CEO of Kinevant Sciences which is focused on developing new therapies for rare inflammatory disorders. Prior to joining Kinevant, he was the CEO of Respivant/Patara Pharma, Elevation Pharma, and Mpex Pharma which developed new medicines for pulmonary fibrosis, chronic obstructive pulmonary disease, and cystic fibrosis, respectively -- with several approved and on the market. He earned a B.A. from Baylor University and an M.B.A. from Harvard Business School.